Oxford BioDynamics PLC PDMR Dealing (1593Q)
June 17 2020 - 1:00AM
UK Regulatory
TIDMOBD
RNS Number : 1593Q
Oxford BioDynamics PLC
17 June 2020
17 June 2020
Oxford BioDynamics Plc
( "OBD" or the "Company" and, together with its subsidiaries,
the "Group")
PDMR Dealing
Oxford BioDynamics Plc (AIM: OBD) announces that it has received
notice that Paul Stockdale, Chief Financial Officer, has purchased
5,000 Ordinary Shares of 1 pence each ("shares") at an average
price of 64.95p per share.
Following this transaction, Paul Stockdale is interested in
15,000 Ordinary Shares, representing 0.02% of the Company's current
issued share capital.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further details:
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Paul Stockdale
------------------------------- --------------------------------------
2 Reason for the notification
-----------------------------------------------------------------------
a) Position/status Director/PDMR
------------------------------- --------------------------------------
b) Initial notification/ Initial notification
Amendment
------------------------------- --------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------
a) Name Oxford BioDynamics Plc
------------------------------- --------------------------------------
b) LEI 2138005Y1TK258O5U928
------------------------------- --------------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted
-----------------------------------------------------------------------
a) Description of the Ordinary Shares of 1 pence each
financial instrument, ISIN: GB00BD5H8572
type of instrument
Identification code
------------------------------- --------------------------------------
b) Nature of the transaction Acquisition of ordinary shares
------------------------------- --------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
0.6495 5,000
----------
------------------------------- --------------------------------------
d) Aggregated information Price Volume
- Aggregated volume 0.6495 5,000
- Price -------
------------------------------- --------------------------------------
e) Dates of the transactions 16 June 2020
------------------------------- --------------------------------------
f) Place of the transaction Outside a trading venue
------------------------------- --------------------------------------
For further details please contact:
Oxford BioDynamics Plc
Jon Burrows, CEO
Paul Stockdale, CFO +44 (0)1865 518910
Shore Capital
Nominated Adviser and Broker
Stephane Auton
Edward Mansfield
John More +44 (0)20 7408 4090
FTI Consulting
Financial Public Relations Adviser
Natalie Garland-Collins +44 (0)20 3727 1000
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a
biotechnology company focused on the discovery and development of
epigenetic biomarkers, based on regulatory 3D genome architecture,
for use within the pharmaceutical and biotechnology industry.
The Company's award-winning, proprietary technology platform,
EpiSwitch(TM), offers non-invasive liquid biopsy readouts to the
standards of validated predictive, prognostic and diagnostic
patient stratifications, and aims to accelerate the drug discovery
and development process, improve the success rate of therapeutic
product development and take advantage of the increasing importance
of personalised medicine.
In particular, EpiSwitch(TM) offers non-invasive molecular
read-outs with strong links to clinical outcomes, and helps reduce
time to market, failure rates and the costs at every stage of drug
discovery. Additionally, the technology provides significant
insights into disease mechanisms for drug discovery and product
re--positioning programmes, and enables the personalisation of
therapeutics for patients in the context of challenging pricing
environments where improved clinical outcomes are critical.
In April 2019, Oxford BioDynamics received the Queen's Award for
Enterprise: Innovation. The Queen's Awards for Enterprise are the
most prestigious awards for UK businesses.
The Company is headquartered in the UK and listed on the London
Stock Exchange's AIM under the ticker "OBD". For more information
please visit www.oxfordbiodynamics.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHFFMRTMTJBBTM
(END) Dow Jones Newswires
June 17, 2020 02:00 ET (06:00 GMT)
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From May 2023 to May 2024